Biopharm-trader-sml

[Biopharm-trader-sml @Biopharm_trader]

top three biotech opportunities: $CCCC offers the strongest long-term setup with promising cemsidomide data and cash runway through 2028; $FATE has strong upside potential through its FT819 lupus program; and $PRME gained FDA clearance for PM647, although it remains early-stage

[Biopharm-trader-sml @Biopharm_trader]

$ALT delivered. Strong Phase 2 AUD data, primary endpoint met, and multiple secondary wins. Excited for what’s ahead. #ALT #Biotech

[Usman Ashraf @usmanashraff]

Paper trading for more than a week is making you a worse trader.

Not better. Worse. Here's why.

[Usman Ashraf @usmanashraff]

Forget R multiples when you're starting out. Seriously.

Every guru tells you to aim for 2R, 3R, 4R.

Before you even take the trade you're supposed to know your exact target.

That's bullshit.

If I ask myself before any trade "what's my R multiple target?" I can't answer that. I'd be lying if I said 3R.

After the trade? Sure.

This was a 4R. That was a 15R. But before? Nobody knows.

If you can't even close a trade green yet, stressing about R multiples is like worrying about your marathon pace when you can't jog a mile.

Get in. Get out green. 10%. 15%.

Take it. Build 25 trades of clean data.

The R comes after consistency. Not before.

[TradeZella 🦄 @TradeZella]

@TraderRajeshDev Try telling Zella AI your goal and watch her keep you on track.

She’ll remember it, hold you accountable, and remind you what you're actually working toward.

[TradeZella 🦄 @TradeZella]

6 months from now is built 1 trade at a time.

Zella AI helps make sure those trades are moving in the right direction. 💪

[Usman Ashraf @usmanashraff]

I've seen this pattern with so many traders.

They have a green week. Size up.

Have a red week. Size down.

Blow the account.

Start over with a different number.

3 months go by.

They look at their journal. The stats make no sense.

Win rate looks off. R multiples are all over the place.

Nothing is consistent.

And they blame the strategy.

The strategy was never the problem.

The constantly changing position size made every single stat meaningless.

[Usman Ashraf @usmanashraff]

Your trading data means absolutely nothing if you keep changing your position size every week.

One week it's $8,000.

Next week it's $3,000.

Month before that something completely different.

You don't have data. You have noise.

Here's why this is destroying your progress. 🧵

[TradeZella 🦄 @TradeZella]

Your biggest edge tomorrow is fixing what hurt you yesterday.

Ignore it, and it compounds.

[TradeZella 🦄 @TradeZella]

1/ Trade one strategy you've personally backtested.

ICT, order flow, supply/demand, support/resistance all work. They just fit different personalities.

Pick the one that matches how you think, then run it through enough data that you can prove it has an edge.

[TradeZella 🦄 @TradeZella]

There's a 7-step process that separates traders who stay stuck at breakeven from the ones who actually get profitable.

Most people never build it.

Here's exactly what's on it 🧵

[Biopharm-trader-sml @Biopharm_trader]

$ALT showing strong momentum today, up over 8% and testing the key $3 area. With pemvidutide advancing and Phase 3 plans ahead, this remains one of the more interesting biotech names to watch. Strong volume + catalyst story = worth keeping on the radar. Not financial advice

[TradeZella 🦄 @TradeZella]

@Sholly_Pee1 Pick one. Backtest it. Track it. Refine it. Repeat.

[TradeZella 🦄 @TradeZella]

+$49.9K week after taking heavy red days.

This is why tracking your month visually is so powerful.
You stop overreacting to single sessions 🫡

[Usman Ashraf @usmanashraff]

$34,250🟢
$nvda min range break for longs
$tsla still doesnt like me
$spx shorts break of 30 min range

[TradeZella 🦄 @TradeZella]

Reducing your trade frequency by 50% increased profitability by 30%.

We see this pattern constantly. Here's why: 🧵

[Usman Ashraf @usmanashraff]

"Work on your mindset" is the most generic advice in trading.

It gets thrown at every single struggling trader the same way.

It's like a doctor giving every patient the same medication without asking what's wrong.

Most traders who aren't performing well don't have a psychology problem.

They haven't even reached that level yet.

They're staring at charts they don't actually understand.

Then blaming their mindset because it's the easiest thing to blame.

The real problem? No defined edge.

No market context.

Wrong position sizing.

Three structural problems.

Fix those.

The psychology fixes itself.

[Biopharm-trader-sml @Biopharm_trader]

$ALT just secured $225M in an oversubscribed raise — Phase 3 for pemvidutide is fully funded.
Short-term dilution, long-term acceleration.
Smart money is positioning ahead of MASH data.

[Biopharm-trader-sml @Biopharm_trader]

$ALT quietly building while most are distracted.
Phase 3 MASH ahead, narrative getting stronger.
Early positioning > late chasing.

[TradeZella 🦄 @TradeZella]

@dancooketrades they want better results without better data tracking, and they wonder why nothing changes 😭